|
|
LMQ |
|
Vaxjo ID |
169 |
|
Vaccine Adjuvant Name |
LMQ |
|
Adjuvant VO ID |
VO_0006092
|
|
Description |
A combination vaccine adjuvant that is liposome-based adjuvant of a synthetic TLR agonist and saponin induced a Th1-biased immune response |
|
Stage of Development |
Research |
|
Location Licensed |
Switzerland (Vaccine formulation institute) |
|
Host Species for Testing |
3 |
|
Components |
neutral liposomes containing cholesterol, DOPC, QS21 and 3D6AP |
|
Storage |
2-8C |
|
Preparation |
QS21 added to neutral liposomes, containing MPL (A) prepared by lipid film method using DOPC and cholesterol |
|
Function |
Indirect stimulation via NLRP3 (Saponin) |
| References |
(Lawrenz, 2024): Vaccine Adjuvant Compendium - VAC [https://vac.niaid.nih.gov/view?id=78]
Rivera-Hernandez et al., 2020: Rivera-Hernandez T, Rhyme MS, Cork AJ, Jones S, Segui-Perez C, Brunner L, Richter J, Petrovsky N, Lawrenz M, Goldblatt D, Collin N, Walker MJ. Vaccine-Induced Th1-Type Response Protects against Invasive Group A Streptococcus Infection in the Absence of Opsonizing Antibodies. mBio. 2020; 11(2); . [PubMed: 32156809].
|
|
